news from the crcm

20 February 2025

Pre-maturation funding for Michel Aurrand-Lions’ team: a breakthrough for the LAM

The team has just received pre-maturation funding from Cancéropôle PACA for its project to validate a biomarker predictive of the eligibility of patients with acute myeloid leukemia (AML) for treatment with menin inhibitors.